Tabrecta and Hearing loss - a phase IV clinical study of FDA data

Summary:

Hearing loss is reported as a side effect among people who take Tabrecta (capmatinib hydrochloride), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Calcium, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Hearing loss when taking Tabrecta. It is created by eHealthMe based on reports of 2,093 people who have side effects when taking Tabrecta from the FDA, and is updated regularly.

What is Tabrecta?

Tabrecta has active ingredients of capmatinib hydrochloride. eHealthMe is studying from 2,095 Tabrecta users. Check the latest studies of Tabrecta.

What is Hearing loss?

Hearing loss is found to be associated with 1,355 drugs and 2,378 conditions by eHealthMe. Check the latest studies of Hearing loss.

On Jul, 16, 2026

2,093 people reported to have side effects when taking Tabrecta.
Among them, 42 people (2.01%) have Hearing loss.

Among these 42 people:

How long have people been on Tabrecta when they have Hearing loss? *

What is the gender of people who have Hearing loss when taking Tabrecta? *

female: 21.95 %
male: 78.05 %

What is the age of people who have Hearing loss when taking Tabrecta? *

What are other drugs people take besides Tabrecta? *

Zometa: 21 people, 50.00%
Torsemide: 21 people, 50.00%
Folic Acid: 21 people, 50.00%
Eliquis: 21 people, 50.00%
Calcium: 21 people, 50.00%
Acetaminophen: 18 people, 42.86%
Ofirmev: 16 people, 38.10%
Vitamin D: 7 people, 16.67%
Hydromorphone Hydrochloride: 4 people, 9.52%
Ondansetron: 2 people, 4.76%

What are other side effects people have besides Hearing loss? *

Fluid Retention (an abnormal accumulation of fluid in the blood): 25 people, 59.52%
Oedema Peripheral (superficial swelling): 24 people, 57.14%
Tinnitus (a ringing in the ears): 24 people, 57.14%
Hypoacusis (loss of hearing): 24 people, 57.14%
Lymphoedema (localized fluid retention and tissue swelling): 24 people, 57.14%
Fatigue (feeling of tiredness): 23 people, 54.76%
Weakness: 23 people, 54.76%
Blood Calcium Decreased: 22 people, 52.38%
Dyspnea (difficult or laboured breathing): 22 people, 52.38%
Dizziness: 21 people, 50.00%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 24 people, 57.14%
Back Pain: 21 people, 50.00%
Thrombosis (formation of a blood clot inside a blood vessel): 8 people, 19.05%
Lung Neoplasm Malignant (cancer tumour of lung): 8 people, 19.05%
Venous Thrombosis Limb (blood clot that forms in a vein in the limb): 7 people, 16.67%
Nausea And Vomiting: 2 people, 4.76%
Nausea (feeling of having an urge to vomit): 2 people, 4.76%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 1 person, 2.38%
Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 1 person, 2.38%
Glioblastoma Multiforme (most common and deadliest of malignant primary brain tumours in adults): 1 person, 2.38%

* Approximation only. Some reports may have incomplete information.

Do you take Tabrecta and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tabrecta:

Tabrecta (2,095 reports)

Hearing loss treatments and more:

Hearing loss (30,352 reports)

Browse all side effects of Tabrecta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hearing loss:

Hearing loss (1,355 drugs)

Browse all the conditions that are associated with Hearing loss:

Hearing loss (2,378 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on capmatinib hydrochloride (the active ingredients of Tabrecta) and Tabrecta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.